351 related articles for article (PubMed ID: 16224453)
1. Opinion: anticipating change in drug development: the emerging era of translational medicine and therapeutics.
Fitzgerald GA
Nat Rev Drug Discov; 2005 Oct; 4(10):815-8. PubMed ID: 16224453
[TBL] [Abstract][Full Text] [Related]
2. What's next in translational medicine?
Littman BH; Di Mario L; Plebani M; Marincola FM
Clin Sci (Lond); 2007 Feb; 112(4):217-27. PubMed ID: 17223795
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. Drug discovery alliances.
Jones A; Clifford L
Nat Rev Drug Discov; 2005 Oct; 4(10):807-8. PubMed ID: 16237845
[No Abstract] [Full Text] [Related]
5. The antibiotic pipeline--challenges, costs, and values.
Wenzel RP
N Engl J Med; 2004 Aug; 351(6):523-6. PubMed ID: 15295041
[No Abstract] [Full Text] [Related]
6. In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
Federsel HJ
Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers: a valuable tool in clinical research and medical practice.
Carini C
IDrugs; 2007 Jun; 10(6):395-8. PubMed ID: 17642003
[TBL] [Abstract][Full Text] [Related]
8. Facilitating patient-centered cancer research and a new era of drug discovery.
Niederhuber JE
Oncologist; 2009 Apr; 14(4):311-2. PubMed ID: 19365096
[No Abstract] [Full Text] [Related]
9. The economics of pediatric formulation development for off-patent drugs.
Milne CP; Bruss JB
Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
[TBL] [Abstract][Full Text] [Related]
10. Perestroika in pharma: evolution or revolution in drug development?
FitzGerald GA
Mt Sinai J Med; 2010; 77(4):327-32. PubMed ID: 20687177
[TBL] [Abstract][Full Text] [Related]
11. The state of innovation in drug development.
Kola I
Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690
[TBL] [Abstract][Full Text] [Related]
12. Attrition and translation.
Duyk G
Science; 2003 Oct; 302(5645):603-5. PubMed ID: 14576424
[TBL] [Abstract][Full Text] [Related]
13. Antibiotic development: a victim of market forces?
Tillotson GS
IDrugs; 2008 May; 11(5):340-6. PubMed ID: 18465675
[TBL] [Abstract][Full Text] [Related]
14. Aligning pharmaceutical innovation with medical need.
Nathan C
Nat Med; 2007 Mar; 13(3):304-8. PubMed ID: 17342145
[No Abstract] [Full Text] [Related]
15. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH
Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999
[TBL] [Abstract][Full Text] [Related]
16. Patent reform in the US: what's at stake for pharmaceutical innovation?
Yancey A; Stewart CN
Expert Opin Ther Pat; 2010 May; 20(5):603-8. PubMed ID: 20402544
[TBL] [Abstract][Full Text] [Related]
17. Brazil: An emerging partner in drug R&D.
Rodrigues DG
IDrugs; 2009 Aug; 12(8):497-502. PubMed ID: 19629884
[TBL] [Abstract][Full Text] [Related]
18. Strategies for bringing drug delivery tools into discovery.
Kwong E; Higgins J; Templeton AC
Int J Pharm; 2011 Jun; 412(1-2):1-7. PubMed ID: 21421040
[TBL] [Abstract][Full Text] [Related]
19. Precompetitive research: a new prescription for drug development?
Woodcock J
Clin Pharmacol Ther; 2010 May; 87(5):521-3. PubMed ID: 20407454
[No Abstract] [Full Text] [Related]
20. Re-engineering drug discovery and development.
FitzGerald GA
LDI Issue Brief; 2011 Oct; 17(2):1-4. PubMed ID: 22049582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
